Discover investment opportunities in 2 Dollar Stocks To Buy using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in 2 Dollar Stocks To Buy using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in 2 Dollar Stocks To Buy using our Smart AI Filter.
7 stocks found for "2 Dollar Stocks To Buy"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
2.07 | ±100.0% | -4.2 | 0.00% | |||
1.63 | ±100.0% | -2.5 | 0.00% | |||
1.19 | ±88.4% | -5.2 | 0.00% | |||
0.52 | ±84.5% | -2.2 | 0.00% | |||
1.47 | ±57.7% | 113.3 | 0.00% | |||
0.87 | ±100.0% | -1.1 | 0.00% | |||
1.17 | ±75.5% | -5.0 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Marker Therapeutics, Inc. MRKR on Tuesday provided an update on the progress and clinical observations from the Phase 1 APOLLO study investigating MT-601, a Multi-Antigen Recognizing (MAR)-T cell product, in patients with lymphoma who have relapsed after anti-CD19 CAR-T cell therapy or for whom anti-CD19 CAR-T cell therapy is not an option.
Read moreSenseonics (SENS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Read moreQ: Why might an investor consider buying NBRV stock?
A: Nabriva Therapeutics (NBRV) is a biopharmaceutical company focused on developing novel antibiotics to treat serious infections. Investors may consider it due to its niche market focus and potential for FDA approvals, though it carries high risk due to speculative nature and dependency on drug approval success.
Q: What factors influence SNDL's performance in the stock market?
A: Sundial Growers (SNDL) is impacted by cannabis legislation in North America, market saturation, and consumer demand for cannabis products. Investors might find it intriguing for its potential growth in the expanding cannabis sector, but volatility and regulatory risks are significant considerations.
Q: How does GHSI's sector specificity impact its investment appeal?
A: Guardion Health Sciences (GHSI) operates in the health sciences sector, focusing on nutritional products and medical foods. Its appeal lies in the growing demand for health and wellness products, yet investors should consider competition in the nutraceutical market and product differentiation strategies.
Q: What potential opportunities does ADXS offer to Gen-X investors?
A: Advaxis (ADXS) engages in cancer immunotherapy with developing treatments targeting solid tumors. It might appeal to Gen-X investors interested in innovative healthcare solutions, but they must weigh its clinical trial outcomes, financial sustainability, and competitive pressures within biotechnology.
Q: What makes MARK an interesting pick for technology-focused investors?
A: Remark Holdings (MARK) focuses on digital media and artificial intelligence, offering technology-driven insights and applications. Its attractions include AI trend alignment and potential tech-stack innovations, balanced by challenges in market competition and technology+commercialization synergies.
Q: In terms of media content, how might CIDM influence investment decisions?
A: Cinedigm Corp (CIDM) is involved in content entertainment creation and distribution. Investors might consider its role in video-on-demand and streaming services as appealing, yet should evaluate competition in content delivery platforms and shifting consumer media consumption trends.